Tauopathy refers to a class of neurodegenerative disorders characterized by the accumulation of hyperphosphorylated tau protein within neurons and glial cells[1]. These disorders include Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal syndrome (CBD), Pick's disease, and chronic traumatic encephalopathy (CTE)[2]. The tau protein, encoded by the MAPT (Microtubule-Associated Protein Tau) gene, plays essential roles in microtubule stabilization, axonal transport, and synaptic function[3].
The fundamental pathology in tauopathies involves the aggregation of tau into insoluble fibrils that form neurofibrillary tangles (NFTs), neuropil threads, and dystrophic neurites. These aggregates disrupt neuronal function through multiple mechanisms including microtubule destabilization, impaired axonal transport, synaptic dysfunction, and eventual neuronal death[4].
The human MAPT gene located on chromosome 17q21.31 encodes the tau protein through alternative splicing of exon 10. Six tau isoforms are expressed in the adult brain, distinguished by the presence of 3 or 4 microtubule-binding repeats (3R or 4R tau) and 0, 1, or 2 N-terminal inserts[5]:
In the normal adult brain, the ratio of 3R to 4R tau is approximately 1:1, reflecting balanced splicing regulation[6]. This balance is critical, as dysregulation toward 4R predominance is a hallmark of PSP and CBD, while 3R predominance characterizes Pick's disease.
Tau performs several essential neuronal functions:
Microtubule stabilization: The microtubule-binding repeats (R1-R4) bind to and stabilize microtubules, enabling axonal transport[7].
Axonal transport regulation: Tau modulates the function of motor proteins (kinesin, dynein) that transport cargo along microtubules[8].
Synaptic function: Tau localizes to synapses where it participates in neurotransmitter release and synaptic plasticity[9].
Signal transduction: Tau interacts with various signaling molecules, including Src family kinases and phosphatases[10].
Hyperphosphorylation is the primary modification that converts tau from a functional microtubule-stabilizing protein into a pathological aggregation-prone species[11]. Over 45 serine, threonine, and tyrosine residues can be phosphorylated on tau, with specific phosphorylation patterns correlating with disease progression.
Key kinases regulating tau phosphorylation:
| Kinase | Primary Sites | Role in Tauopathy |
|---|---|---|
| GSK-3β | Ser202, Thr205, Ser396, Ser404 | Primary tau kinase, hyperactive in AD |
| CDK5 | Ser202, Thr205, Ser235 | Activated in neurodegeneration |
| PKA | Ser262, Ser356, Ser214 | Promotes microtubule detachment |
| DYRK1A | Thr212 | Elevated in AD brain |
| MAPK | Ser396, Ser404 | Stress-activated |
Key phosphatases:
The aggregation of tau into fibrils follows a nucleation-dependent polymerization model[13]:
Nucleation: Formation of oligomeric tau species requires overcoming an energy barrier. This is accelerated by:
Elongation: Addition of monomeric tau to growing fibrils. 4R tau aggregates faster than 3R due to additional hexapeptide motifs in the fourth repeat.
Maturation: Formation of stable, protease-resistant fibrils with cross-β sheet architecture.
Distinct tau fibril structures (strains) characterize different tauopathies, as revealed by cryo-electron microscopy[14]:
Alzheimer's disease:
Progressive supranuclear palsy:
Corticobasal syndrome:
Pick's disease:
These disorders feature predominant 4R tau accumulation:
Hyperphosphorylated tau loses its ability to bind and stabilize microtubules, leading to:
Tau pathology disrupts both anterograde (kinesin-dependent) and retrograde (dynein-dependent) transport:
Tau aggregates at synapses contribute to:
Multiple pathways lead to tauopathy-associated neuronal death:
The MAPT gene on chromosome 17q21.31 encodes tau and numerous mutations cause or predispose to tauopathies[21]. Over 50 pathogenic MAPT mutations have been identified:
Splicing mutations (alter tau isoform ratios):
Aggregation-promoting mutations:
The H1 haplotype of MAPT (a 500 kb inversion polymorphism) is strongly associated with PSP, CBD, and AGD[22]. The H1c sub-haplotype specifically increases risk for PSP with an odds ratio of approximately 5.5. This haplotype influences MAPT expression and alternative splicing, favoring 4R tau production.
Genome-wide association studies have identified multiple tauopathy risk loci[23]:
Tauopathy is associated with widespread DNA methylation changes[24]:
Histone acetylation and methylation patterns are altered in tauopathies:
MicroRNAs (miRNAs) regulate tau pathology[25]:
Long non-coding RNAs (lncRNAs):
Tauopathy is closely linked to metabolic dysfunction[26]:
Key mechanisms:
Mitochondria are severely affected in tauopathies:
Therapeutic implications:
Brain insulin resistance is a key feature[27]:
Sleep disruption and tauopathy have a bidirectional relationship[28]:
The suprachiasmatic nucleus is affected in tauopathies:
Sleep interventions may benefit tauopathy:
Tau PET ligands enable in vivo visualization of tau pathology[29]:
FDA-approved ligands:
Emerging ligands:
Limitations:
CSF analysis provides molecular profiling[30]:
Tau species:
Utility:
Emerging blood tests offer accessible diagnostics[31]:
Key biomarkers:
Platforms:
Active vaccination:
Passive immunotherapy:
Tau aggregation inhibitors:
Kinase inhibitors:
Paclitaxel derivatives:
ASO therapy:
Viral vector approaches:
3xTg-AD mice:
P301S tau mice:
rTg4510 mice:
Inoculation studies:
Adeno-associated virus (AAV) models:
Tau exhibits prion-like properties[32]:
Tau spreads between neurons via:
Tau pathology follows brain networks:
Therapeutic strategies targeting propagation:
Microglia play complex roles in tauopathy[33]:
Pro-inflammatory (M1-like) microglia:
Neuroprotective (M2-like) microglia:
The complement cascade is heavily involved:
Key cytokines in tauopathy:
Anti-inflammatory approaches:
Cerebral amyloid angiopathy (CAA) frequently co-occurs with tauopathy and contributes to disease progression[34]. The accumulation of amyloid-beta in cerebral blood vessels not only increases hemorrhage risk but also disrupts vascular clearance pathways for both amyloid and tau. CAA-associated vascular dysfunction impairs the glymphatic system, reducing nocturnal clearance of toxic proteins from the brain interstitium.
Tauopathy is associated with progressive blood-brain barrier (BBB) dysfunction[35]. Pericyte loss and endothelial tight junction disruption allow peripheral proteins and immune cells to enter the brain, exacerbating neuroinflammation. BBB breakdown correlates with cognitive decline and predicts rapid progression in tauopathies.
Hypertension, diabetes, and hyperlipidemia all accelerate tau pathology:
Iron accumulation in the aging brain contributes to tau pathology through oxidative stress mechanisms[36]. Excess iron catalyzes the formation of reactive oxygen species that promote tau phosphorylation and aggregation. Iron regulatory proteins (IRP1, IRP2) show altered expression in tauopathies, disrupting cellular iron homeostasis.
Divalent metal ions directly influence tau aggregation:
Metal chelation therapy has been explored in tauopathies:
The default mode network (DMN) is particularly vulnerable in tauopathies[37]. Early tau accumulation in the entorhinal cortex and posterior cingulate disrupts DMN connectivity, correlating with episodic memory deficits. Functional connectivity changes precede structural atrophy, providing potential early biomarkers.
Tau pathology spreads along connected neural networks:
Network-based approaches offer novel therapeutic strategies:
| Protein/Gene | Function | Disease Link |
|---|---|---|
| MAPT | Microtubule-associated protein tau | All tauopathies |
| GSK3B | Tau kinase | AD, PSP |
| CDK5R1 | CDK5 activator p35 | Neurodegeneration |
| PPP2CA | PP2A catalytic subunit | Tau dephosphorylation |
| FYN | Src family kinase | Tau phosphorylation |
Ballard et al. [ Lancet (2005)](https://doi.org/10.1016/S0140-6736(05). 2005. ↩︎
Goedert et al. Nat Rev Neurosci (2017). 2017. ↩︎
Mandelkow & Mandelkow, Cold Spring Harb Perspect Med (2012). 2012. ↩︎
Arendt et al. Nat Rev Neurosci (2016). 2016. ↩︎
Goedert et al. [ Neuron (1989)](https://doi.org/10.1016/0896-6273(89). 1989. ↩︎
Sultan et al. J Neurochem (2011). 2011. ↩︎
Weingarten et al. Proc Natl Acad Sci USA (1975). 1975. ↩︎
Stamer et al. J Cell Biol (2002). 2002. ↩︎
Tai et al. J Exp Med (2012). 2012. ↩︎
Lee et al. J Neurosci (2011). 2011. ↩︎
Hanger et al. Trends Neurosci (2009). 2009. ↩︎
Fitzpatrick et al. Nature (2017). 2017. ↩︎
Litvan et al. Neurology (1996). 1996. ↩︎
Riley et al. Neurology (1994). 1994. ↩︎
Dickson et al. Brain (2012). 2012. ↩︎
Cash et al. J Neurosci (2003). 2003. ↩︎
Mandelkow et al. Traffic (2003). 2003. ↩︎
Tai et al. Nat Rev Neurol (2014). 2014. ↩︎
Rademakers et al. Nat Rev Neurol (2005). 2005. ↩︎
Pike et al. Brain (2021). 2021. ↩︎
Ferrari et al. Nat Genet (2014). 2014. ↩︎
De Vivo et al. Nat Rev Neurol (2019). 2019. ↩︎
Siedlecki-Wullich et al. J Neurosci (2019). 2019. ↩︎
Ju et al. Sci Transl Med (2017). 2017. ↩︎
Leuzy et al. Nat Rev Neurol (2019). 2019. ↩︎
Blennow et al. Nat Rev Neurol (2021). 2021. ↩︎
Karikari et al. Nat Med (2020). 2020. ↩︎
Frost et al. J Biol Chem (2009). 2009. ↩︎
Hyman et al. Nat Rev Neurol (2021). 2021. ↩︎
Cai et al. Nat Rev Neurol (2022). 2022. ↩︎
Biglari et al. J Neurochem (2022). 2022. ↩︎
Lovell et al. J Alzheimers Dis (2009). 2009. ↩︎
Harris et al. Brain (2020). 2020. ↩︎